Outset Medical, Inc. (NASDAQ:OM) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have earned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.00.

OM has been the subject of a number of research analyst reports. Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings cut shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st.

Outset Medical Price Performance

Shares of OM stock opened at $3.21 on Monday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.11 and a current ratio of 5.19. Outset Medical has a fifty-two week low of $3.00 and a fifty-two week high of $16.16. The firm has a market cap of $60.35 million, a P/E ratio of -0.78 and a beta of 1.90. The business’s 50 day moving average price is $4.29 and its 200-day moving average price is $4.19.

Outset Medical (NASDAQ:OM) last announced its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The business had revenue of $31.64 million for the quarter, compared to the consensus estimate of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. On average, equities research analysts anticipate that Outset Medical will post -3.81 earnings per share for the current year.

Institutional Investors Weigh In On Outset Medical

A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in Outset Medical during the second quarter valued at $34,000. BNP Paribas Financial Markets boosted its holdings in shares of Outset Medical by 7,013.8% in the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after buying an additional 2,034 shares during the last quarter. New York State Common Retirement Fund purchased a new position in shares of Outset Medical during the 2nd quarter worth $108,000. Los Angeles Capital Management LLC purchased a new position in Outset Medical during the fourth quarter valued at $29,000. Finally, Quantbot Technologies LP purchased a new position in shares of Outset Medical during the 2nd quarter valued at about $152,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.